Recon: FDA approves Sanofi’s Dupixent for rare skin disorder; Eisai, Biogen announce positive Phase III results for Alzheimer’s drug
ReconJoanne S. Eglovitch
Biologics/ biosimilars/ vaccinesBiotechnologyDiagnostics/IVDsEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/Policy